Study S000543

A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07357740
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: WITHDRAWN
Enrollment: 0
Start: 2026-08-27
Primary completion: 2027-08-25
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:CagriSema; DRUG:Placebo CagriSema
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1323-3766; OTHER:2025-522570-37; NIH:2025

Registered primary outcomes

Change in glycated haemoglobin (HbA1c) [Baseline to week 28]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.